Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Allied Biomedical Research

Neither a doctor nor a teaching hospital

Research payments

$4,069,925

95 payments

Through program year 2025, Allied Biomedical Research is reported as receiving $4,069,925 in research payments, across 95 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $491,685 15
2024 Research $622,541 6
2023 Research $533,778 11
2022 Research $680,031 32
2021 Research $652,572 17
2020 Research $1,089,319 14

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eisai Inc. $3,368,912 63 payments
  2. AbbVie, Inc. $491,685 15 payments
  3. Genentech, Inc. $183,913 11 payments
  4. Boehringer Ingelheim International GmbH $15,665 2 payments
  5. Ge Healthcare $9,750 4 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $3,333,592 61 payments
  2. Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder $193,606 6 payments
  3. Postgraduate Roll Over Study $183,913 11 payments
  4. M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) $177,910 4 payments
  5. Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) $78,258 3 payments
  6. An Open-Label Study To Evaluate the Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies or Parkinson's Disease Dementia With or Without Amyloid Copathology $35,320 2 payments
  7. Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder $29,379 1 payment
  8. Slope Estimation and Homogeneity Study $15,665 2 payments
  9. Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder $12,532 1 payment
  10. A Phase 3| Open Label| Multicenter Study of Flurpiridaz (18F) Injection for Positive Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease $9,750 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record